Product image of Linaglitpin Intas (Linagliptin) supplied by GNH India

Linaglitpin Intas

Active Ingredient:
Linagliptin
Origin:
EU

Linaglitpin Intas (Linagliptin)

Linagliptin, the active ingredient in Linaglitpin Intas, is a Dipeptidyl peptidase-4 (DPP-4) inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adults.
GNH India supplies Linaglitpin Intas as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Intas Third Party Sales 2005, S.L.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linagliptin is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder affecting glucose regulation.

  • Type 2 diabetes mellitus: improves glycaemic control when used as monotherapy.
  • Type 2 diabetes mellitus combined with metformin: provides additional HbA1c reduction.
  • Type 2 diabetes mellitus with lifestyle therapy: assists patients in achieving target blood‑glucose levels alongside diet and exercise.

How It Works

  • Linagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, preventing the breakdown of incretin hormones such as GLP‑1 and GIP. Elevated incretin levels enhance glucose‑dependent insulin secretion from pancreatic β‑cells and suppress glucagon release from α‑cells, leading to reduced post‑prandial glucose excursions and overall improved glycaemic control.

Side Effects

Adverse reactions may occur with linagliptin therapy.

Common Side Effects

  • Nasopharyngitis: mild upper‑respiratory infection symptoms.
  • Headache: transient cranial discomfort.
  • Upper respiratory tract infection: cough, sore throat, or congestion.
  • Dizziness: occasional light‑headedness.
  • Gastrointestinal discomfort: nausea, abdominal pain, or diarrhoea.
  • Back pain: musculoskeletal discomfort.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring immediate medical attention.
  • Severe allergic reactions: angioedema, Stevens‑Johnson syndrome, or toxic epidermal necrolysis.
  • Hepatic injury: elevated liver enzymes or jaundice.
  • Severe hypoglycaemia: especially when combined with insulin or sulfonylureas.
  • Bullous pemphigoid: rare autoimmune skin disorder.

Precautions & Warnings

Before initiating linagliptin, consider the following precautions.

  • Renal impairment: monitor renal function and adjust therapy as needed.
  • Hepatic impairment: use with caution in patients with liver disease.
  • Risk of hypoglycaemia: avoid dose‑related hypoglycaemia when combined with insulin or sulfonylureas.
  • History of pancreatitis: discontinue if signs of pancreatitis develop.
  • Pregnancy and lactation: consult prescriber; safety data are limited.
  • Store at ambient temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Linagliptin may interact with other medicines; review the following categories.

Major Interactions (Avoid)

  • Insulin: may increase risk of severe hypoglycaemia.
  • Sulfonylureas: combined use can potentiate hypoglycaemic episodes.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise linagliptin plasma levels.

Moderate Interactions (Monitor Closely)

  • Rifampin: may reduce linagliptin efficacy by inducing metabolism.
  • Diuretics: can affect glucose control; monitor blood sugar.
  • ACE inhibitors: observe renal function and electrolytes during co‑administration.

Frequently Asked Questions

Linaglitpin Intas contains linagliptin, a DPP‑4 inhibitor indicated for the treatment of type 2 diabetes mellitus in adults. It is used to improve glycaemic control when diet and exercise alone are insufficient, either as monotherapy or in combination with other antidiabetic agents.

Linagliptin works by selectively blocking the DPP‑4 enzyme, which normally degrades the incretin hormones GLP‑1 and GIP. By preserving these hormones, linagliptin enhances glucose‑dependent insulin secretion and reduces glucagon release, leading to lower post‑prandial blood glucose levels.

The dosage of linagliptin is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose without medical advice.

Safety data for linagliptin during pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified prescriber after a thorough risk‑benefit assessment.

To order Linaglitpin Intas, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Linagliptin shares the same class mechanism as other DPP‑4 inhibitors but has a distinct pharmacokinetic profile, including a long half‑life that allows once‑daily dosing without dose adjustment in mild to moderate renal impairment. Efficacy and safety are comparable, though individual patient factors guide the choice of agent.

Linaglitpin Intas should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Linaglitpin Intas is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious adverse events include pancreatitis, severe allergic reactions such as angioedema or Stevens‑Johnson syndrome, hepatic injury, and rare cases of bullous pemphigoid. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, or signs of an allergic reaction.

Linagliptin is contraindicated in individuals with a known hypersensitivity to linagliptin or any component of the formulation. Caution is advised for patients with a history of pancreatitis, severe hepatic disease, or those taking concomitant medications that may cause significant drug interactions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT